Leukotriene modifiers, such as Montelukast (which specifically targets CysLT1) and Zileuton (a competitive inhibitor of 5-LO), are important anti-inflammatory drugs that are used for the treatment of atopic asthma (Dube et al., 1999) or as combination therapy in asthma. This evidence concerns the gene CYSLTR1 and asthma.